psorcon e- diflorasone diacetate cream

দেশ: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

diflorasone diacetate (UNII: 7W2J09SCWX) (diflorasone - UNII:T2DHJ9645W)

থেকে পাওয়া:

Dermik Laboratories, Inc.

INN (আন্তর্জাতিক নাম):

diflorasone diacetate

ফার্মাসিউটিকাল ফর্ম:

CREAM

রচনা:

0.5 mg in 1 g

প্রশাসন রুট:

TOPICAL

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

পণ্য সারাংশ:

Psorcon E Emollient Cream is available in the following size tubes: Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].

পণ্য বৈশিষ্ট্য

PSORCON E- DIFLORASONE DIACETATE CREAM
DERMIK LABORATORIES, INC.
----------
PSORCON E EMOLLIENT CREAM
(DIFLORASONE DIACETATE CREAM) 0.05%
NOT FOR OPHTHALMIC USE
DESCRIPTION
Each gram of PSORCON E Emollient Cream contains 0.5 mg diflorasone
diacetate in a cream base.
Chemically, diflorasone diacetate is:
6α,9-difluoro-11β,17,21-trihydroxy-16β-methyl-pregna-1,4-
diene-3,20-dione 17,21-diacetate. The structural formula is
represented below:
Each gram of PSORCON E Emollient Cream contains 0.5 mg diflorasone
diacetate in a hydrophilic
vanishing cream base of propylene glycol, stearyl alcohol, cetyl
alcohol, sorbitan monostearate,
polysorbate 60, mineral oil and purified water.
CLINICAL PHARMACOLOGY
Topical corticosteroids share anti-inflammatory, antipruritic and
vasoconstrictive actions.
The mechanism of anti-inflammatory activity of the topical
corticosteroids is unclear. Various
laboratory methods, including vasoconstrictor assays, are used to
compare and predict potencies and/or
clinical efficacies of the topical corticosteroids. There is some
evidence to suggest that a
recognizable correlation exists between vasoconstrictor potency and
therapeutic efficacy in man.
PHARMACOKINETICS
The extent of percutaneous absorption of topical corticosteroids is
determined by many factors
including the vehicle, the integrity of the epidermal barrier, and the
use of occlusive dressings.
Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease
processes in the skin increase percutaneous absorption. Occlusive
dressings substantially increase the
percutaneous absorption of topical corticosteroids. Thus, occlusive
dressings may be a valuable
therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE
AND ADMINISTRATION.)
Once absorbed through the skin, topical corticosteroids are handled
through pharmacokinetic pathways
®
similar to systemically administered corticosteroids. Corticosteroids
are bound to plasma proteins in
varying degrees. They are metabolized primarily in the